Delcath Systems Announces 2025 Financial Guidance

The latest update is out from Delcath Systems ( (DCTH) ).

On May 22, 2025, Delcath Systems announced its full-year 2025 financial guidance, projecting total revenue between $94 to $98 million, marking a significant increase of over 150% from 2024. The company also plans to enter into a National Medicaid Drug Rebate Agreement with the Centers for Medicare & Medicaid Services, expected to take effect in the third quarter of 2025, which aims to expand patient access and accelerate the adoption of its HEPZATO treatment in the U.S.

The most recent analyst rating on (DCTH) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Delcath Systems stock, see the DCTH Stock Forecast page.

Spark’s Take on DCTH Stock

According to Spark, TipRanks’ AI Analyst, DCTH is a Neutral.

Delcath Systems exhibits strong revenue growth and operational momentum, supported by a positive earnings call. However, significant challenges remain with profitability and cash flow management. Technical indicators show overbought conditions, and valuation concerns persist due to the negative P/E ratio. Investors should closely monitor cash flow improvements and strategic execution.

To see Spark’s full report on DCTH stock, click here.

More about Delcath Systems

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Its proprietary products, HEPZATO KIT and CHEMOSAT, are designed to deliver high-dose chemotherapy to the liver while minimizing systemic exposure and side effects. HEPZATO KIT is approved in the U.S. for treating specific liver metastases, while CHEMOSAT is approved in Europe for a broader range of liver cancers.

Average Trading Volume: 473,379

Technical Sentiment Signal: Hold

Current Market Cap: $625.8M

See more insights into DCTH stock on TipRanks’ Stock Analysis page.